On November 1, 2017 MacroGenics, Inc. (Nasdaq: MGNX) reported that on Wednesday, November 8, 2017, the Company will release its financial results for the quarter ended September 30, 2017 (Press release, MacroGenics, NOV 1, 2017, View Source [SID1234521439]). The Company’s management team will host a conference call discussing the Company’s financial results and recent corporate developments on Wednesday, November 8, 2017 at 4:30 pm (ET). The call can be accessed by dialing (877) 303-6253 (domestic) or (+1) (973) 409-9610 (international) five minutes prior to the start of the call and providing the conference ID: 5477659.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The recorded, listen-only webcast of the conference call can be accessed under “Events & Presentations” in the Investors section of the Company’s website at View Source A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company’s website for 30 days following the call.

Fate Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 1, 2017 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, reported that members of the management team will present at the following upcoming investor conferences (Press release, Pieris Pharmaceuticals, NOV 1, 2017, View Source [SID1234521395]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stifel Healthcare Conference, Tuesday, November 14, 10:15 am EST at Lotte New York Palace Hotel, New York City. A webcast of the Company’s presentation will be available at this link.

Jefferies London Healthcare Conference, Thursday, November 16, 8:40 am GMT at the Waldorf Hilton, Aldwych, London.

Evercore ISI Biopharma Catalyst / Deep Dive Conference, Wednesday, November 29, 1:15 pm EST at the Boston Harbor Hotel, Boston.

On November 1, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at 11:35 a.m. Mountain time (10:35 a.m. Pacific time) in Scottsdale, AZ (Press release, Ignyta, NOV 1, 2017, View Source [SID1234521432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available during the presentation in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.

Pain Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Pain Therapeutics, 2017, NOV 1, 2017, View Source [SID1234521417]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!